Akouos, Inc., a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, announced it has raised $105 million in an oversubscribed Series B financing.
Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based biotech unveiled the series A round alongside the appointment of a Spark Therapeutics co-founder and other organizational changes.